Quantcast
Last updated on April 21, 2014 at 4:55 EDT

Latest Targeted therapy Stories

Uncommon Antidepressants Could Become Cancer Treatments
2013-09-27 14:23:35

Michael Harper for redOrbit.com - Your Universe Online Two antidepressants that aren’t often prescribed to patients could soon be recommended to serve a completely different purpose; ward off small-cell lung cancer (SCLC). A new bioinformatics study has found these FDA-approved medications are molecularly predisposed to treat SCLC. By investigating the biochemical foundation of these medications, researchers may be able to repurpose the drug without the lengthy and expensive process...

2013-09-25 12:28:16

Increased Incidence and the Launches of Premium-Priced Agents Will Sustain Four Percent Annual Growth in the Turkish Market, According to a New Report from Decision Resources BURLINGTON, Mass., Sept. 25, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that, from 2012 to 2017, the colorectal cancer (CRC) market in Turkey will grow at an annual rate of four percent, reaching $90 million...

2013-09-23 12:25:42

ALBANY, New York, September 23, 2013 /PRNewswire/ -- New Report Added in ResearchMoz Reports Database Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies ResearchMoz announces that it has published a new study Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted...

2013-09-13 08:14:51

Results to be presented at ECC2013 will pave the way for personalized treatment A further step along the road to the personalization of cancer medicine, where treatment is based on the individual molecular characteristics of tumors rather than their primary site, will be presented at the 2013 European Cancer Congress (ECC2013), which starts on Friday 27 September in Amsterdam, The Netherlands. Dr Christophe Le Tourneau, Head of the Phase I Programme at the Institut Curie, Paris, France,...

2013-09-11 08:27:59

Epigenetic Mechanism with Potential to Reverse Resistance to Hormonal Therapy in Patients with Limited Treatment Options WALTHAM, Mass., Sept. 11, 2013 /PRNewswire/ -- Syndax Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated entinostat as a Breakthrough Therapy for the treatment of locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer when added to exemestane in postmenopausal women whose disease has...

2013-09-04 08:31:53

Agreement Includes a Joint Development Committee and Eddingpharm's Participation in Global Registration Trials WALTHAM, Mass., Sept. 4, 2013 /PRNewswire/ -- Syndax Pharmaceuticals Inc., which is developing epigenetic therapies for treatment-resistant cancers and Eddingpharm, a leading specialty pharmaceutical company in China, entered into a licensing, development and commercialization agreement that gives Eddingpharm exclusive rights to develop, market and sell entinostat in China and...

2013-08-27 08:27:31

Company Prepares for Pivotal Phase 3 Study of Entinostat, Most Advanced HDAC Inhibitor in Development for ER+ Metastatic Breast Cancer WALTHAM, Mass., Aug. 27, 2013 /PRNewswire/ -- Syndax Pharmaceuticals Inc., which is developing epigenetic therapies for treatment-resistant cancers, today announced it has secured a $26.6 million Series B financing. Participating investors included Domain Associates, MPM Capital, Forward Ventures and RusnanoMedInvest (RMI). Syndax plans to use the...

2013-08-14 08:29:22

ROCKVILLE, Md., Aug. 14, 2013 /PRNewswire/ -- EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, today reported financial results for the three and six-month periods ended June 30, 2013. (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO) EntreMed reported a net loss for the second quarter of 2013 of ($1.9 million), or ($0.07) per share. This compares with a net loss of ($10.5...

2013-08-07 10:44:28

New findings could lead to drugs that fight back when tumors don't respond to treatment Cancer drugs known as ErbB inhibitors have shown great success in treating many patients with lung, breast, colon and other types of cancer. However, ErbB drug resistance means that many other patients do not respond, and even among those who do, tumors commonly come back. A new study from MIT reveals that much of this resistance develops because a protein called AXL helps cancer cells to circumvent...

2013-08-06 04:20:03

Singapore, Aug 6, 2013 - (ACN Newswire) - A team of scientists led by Associate Professor Zeng Qi(1) from A*STAR's Institute of Molecular and Cell Biology (IMCB) have discovered a new biomarker which will help physicians predict how well cancer patients respond to cancer drugs. Having the means to identify patients who are most likely to benefit from currently available cancer drugs not only reduces substantially the healthcare cost for the patient, it could mean saving precious lives by...